We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

The Pioneers of Portable
Neurostimulation
Pushing treatment options to rehabilitate lost function into the future
Solutions Backed
by Science
Dedicating years of research to ensure safety and efficacy
Enhancing the
Human Experience
Empowering individuals with neurological disorders and traumatic brain injury (mmTBI) by increasing their independence and quality of life
Real Patients with
Real Results*
“PoNS Therapy™ enabled me to improve my walking. Some tasks seem easier, which make my daily life better.”
Helius Medical Technologies Logo

We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Our Origin

Helius’ origin stems from the early 1990s, and the pioneering work in neuroplasticity at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. This work led to the development of the investigational Portable Neuromodulation Stimulator (PoNS®), that delivers neurostimulation via the tongue, which has been shown in clinical studies to improve the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury.

Helius News

-- Total Q3 revenue up 80% over prior year -- -- Cash on hand expected to fund operations through 2023 -- -- Company to host call at 8:30am today -- NEWTOWN, Pa. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company

November 14, 2022

-- Fourth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects’ adherence to PoNS ® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Helius Medical

November 9, 2022

-- Third Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa. , Nov. 08, 2022 (GLOBE NEWSWIRE) -- Helius Medical

November 8, 2022

Physical Therapists Who Visit Booth 512 Can Sign Up for Free Online PoNS Therapy™ Training NEWTOWN, Pa. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) will showcase its innovative new Portable Neuromodulation Stimulator (PoNS®) at the 99 th annual American Congress

November 3, 2022

Careers at Helius Medical

At Helius, you can have a positive impact on the lives of millions of people around the globe who rely on our innovations for their recovery. Helius brings together the world’s best talent to succeed in our ongoing mission. Together, we work passionately to develop and deliver easy-to-use technology for neurological wellness. If you want to join us in our mission, we want to hear from you.